Afluria quadrivalent vaccine market forecast points to faster growth in Asia-Pacific

The Business Research Company says the global Afluria Quadrivalent vaccine market is being shaped by rising flu incidence, broader pediatric immunization and higher healthcare spending. North America led the market in 2025, while Asia-Pacific is projected to grow the fastest through 2035.

Why it matters: - Afluria Quadrivalent is positioned to benefit from a wider push for flu vaccines that protect against more strains, which can improve seasonal coverage and reduce infection risk. - The market’s growth matters for vaccine makers, public health buyers and healthcare systems that are expanding immunization programs. - The report says demand is rising across high-risk groups, children and healthcare workers as influenza burden remains elevated.

What happened: - The Business Research Company published its Afluria Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 29, 2026. - The report analyzes market trends, segment details, business strategies and geographic outlook for Afluria Quadrivalent. - A free sample of the report is available here. - The full report is available here.

The details: - Afluria Quadrivalent protects against four influenza strains: H1N1, H3N2 and two influenza B strains. - The vaccine is administered by injection. - The vaccine is approved for people ages six months and older. - The report links past market growth to limitations in trivalent flu vaccines, recurrent outbreaks involving multiple strains, higher hospitalization rates, established immunization schedules and public vaccination programs. - The report expects future growth from demand for broader strain coverage, increased vaccination efforts among healthcare workers, expanded pediatric vaccination, government procurement growth and new vaccine delivery methods. - Key forecast-period trends include broader adoption of quadrivalent vaccines, stronger protection against multiple influenza strains, higher vaccination rates among high-risk groups, larger government immunization campaigns and vaccine formulation advances. - The report says rising global influenza prevalence is a major demand driver, helped by virus mutations, seasonal conditions and vaccination gaps. - In November 2024, the UK Health Security Agency reported influenza positivity rates averaging 3.9% in week 46, up from 3.3% the prior week. - In the same UK report, positivity among children ages 5 to 14 rose from 8.8% to 11.6%. - The report also points to rising birth rates as a driver because more children need influenza immunization. - In October 2024, the Australian Bureau of Statistics reported 24,737 Aboriginal and Torres Strait Islander births registered in 2023, up 349 from 2022. - Higher healthcare spending is another growth factor because it supports broader access to seasonal influenza vaccination. - In May 2024, the UK Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, compared with 0.9% growth in the prior period. - In 2025, North America was the largest regional market for Afluria Quadrivalent. - The Asia-Pacific region is projected to be the fastest-growing market over the forecast period. - Other regions covered include Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 market report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables.

Between the lines: - The report’s growth thesis centers on a familiar vaccine-market pattern: higher disease burden and broader public-sector immunization spending tend to lift demand. - North America’s current lead suggests established vaccination infrastructure, while Asia-Pacific’s projected growth points to room for expansion in coverage and procurement. - The inclusion of more advanced analytics tools in the report package signals that buyers want more planning support, not just market sizing.

What's next: - The report expects quadrivalent vaccines to gain further adoption as public health systems prioritize broader flu protection. - Demand should continue to track flu activity, pediatric vaccination efforts and government purchasing decisions. - Regional growth is likely to remain strongest in Asia-Pacific if immunization access and procurement continue to expand.

The bottom line: - Afluria Quadrivalent sits in a market that is being pushed by stronger flu prevention efforts, rising vaccination need and broader healthcare spending, with Asia-Pacific emerging as the key growth market.